FindTrial
Sign In

Application of new Golgi protein markers in early diagnosis and gene therapy of prostate cancer

Application of new Golgi protein markers in early diagnosis and gene therapy of prostate cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800017693
Enrollment
Unknown
Registered
2018-08-09
Start date
2018-08-01
Completion date
Unknown
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

Gold Standard:Confirmed prostate cancer patients
Index test:psa
GOLPH2
IL-6

Sponsors

Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: Urine samples from 100-200 patients with prostate cancer at different stages were collected before and after CRPC, 100-200 patients with benign prostatic hyperplasia and 100-200 healthy people.

Exclusion criteria

Exclusion criteria: A febrile patient with intraoperative complications of massive hemorrhage.

Design outcomes

Primary

MeasureTime frame
PSA;GOLPH2;SPE, SEN, ACC;—

Countries

China

Contacts

Public ContactWenzhi Li

Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine

drmrna@126.com+86 13501698916

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026